Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 12, 2006. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within a retirement plan rather than general corporate financial performance.
Material Changes
The filing details a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan. This resulted in an increase in the notional allocation of Ordinary Share ADRs on June 2, 2006, at a price of $55.99 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a compliance notification pursuant to Disclosure Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the transaction date of June 2, 2006, and the share price of $55.99 per ADR.
- Confirm the identity of the notified individuals, including Dr. R. Greig.
- Note that this filing does not contain financial results or strategic updates for the company.